Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).

Abstract

PURPOSE We aimed to identify gene expression signatures associated with angiogenesis and hypoxia pathways with predictive value for treatment response to bevacizumab/erlotinib (BE) of nonsquamous advanced non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN Whole-genome gene expression profiling was performed on 42 biopsy samples (from SAKK 19… (More)
DOI: 10.1158/1078-0432.CCR-14-3135

Topics

Cite this paper

@article{Franzini2015GeneES, title={Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).}, author={Anca Franzini and Florent Baty and Ina Iuliana Macovei and Oliver D{\"{u}rr and Cornelia Dr{\"{o}ge and Daniel C. Betticher and Bogdan Dragoş Grigoriu and Dirk Klingbiel and Francesco Zappa and Martin H. Brutsche}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2015}, volume={21 23}, pages={5253-63} }